Urogen Pharma Ltd at Goldman Sachs Global Healthcare Conference Transcript
Good afternoon, everyone. We'll continue with the next session. My name is Paul Choi. I'm the U.S. mid-cap biotechnology analyst at Goldman Sachs, and with me from the team in the audience is Corinne Jenkins.
Our next session is with UroGen, and we are pleased to have them here, I believe, first time ever. And representing the management team here to my left is Liz Barrett, CEO; and I think is a familiar face to many investors; and then to her left, Dr. Mark Schoenberg, CMO, to discuss the story here. And perhaps where we'll begin with is have Liz give maybe an overview of the company and an introduction for those of you who may not be familiar with the story. And maybe we can start with that, and then we'll go into Q&A after.
Sure. Absolutely. Thanks, Paul, and thanks for having us here. UroGen is, I would say, a clinical but almost to be a commercial-stage organization where we are really focused on
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
